慢阻肺药物治疗试验结局更新:COPD研究者报告——对2008年美国胸科学会/欧洲呼吸学会声明的再评估
本文是对2008年美国胸科学会/欧洲呼吸学会关于慢阻肺药物治疗试验结局声明的更新报告。作者通过非系统性的文献检索,重新评估了临床试验终点、结局和生物标志物的局限性,并描述了可用于评估个体化治疗的新工具。文章指出「无标签」可治疗特征方法正成为精准医学的重要步骤,未来试验应聚焦高患病率的可治疗特征,联合终点等新工具有助于识别适合新药治疗的患者。
要点
- 2008年ATS/ERS声明发表后慢阻肺诊疗向个体化转变,需更新试验终点。
- 重新评估了原有终点、结局和生物标志物的局限性并描述新工具。
- 未来试验应聚焦高患病率可治疗特征,联合终点有助于精准识别患者。
核心结论
- 「无标签」可治疗特征方法正成为精准医学的重要步骤,未来临床试验应聚焦高患病率的可治疗特征。
- 新工具尤其联合终点的使用,可帮助更好地识别适合接受新药治疗的患者。
研究设计与样本
- 本文为美国胸科学会/欧洲呼吸学会任务组的更新报告,非系统评价。
主要发现
- 作者重新审视了临床试验终点、结局和生物标志物,并强调了2008年ATS/ERS任务组文件中部分内容的局限性。
- 文章描述了可能有助于评估个体化治疗的新工具。
临床怎么用
- 临床研究者设计慢阻肺药物试验时,可考虑聚焦高患病率可治疗特征并采用联合终点等新工具。
局限性
- 文献检索策略主要由作者基于个人意见和评估构建,未采用集中文献审查或统一的证据纳入/排除标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: In 2008, a dedicated American Thoracic Society/European Respiratory Society task force published a paper on the possible use and limitations of clinical outcomes and biomarkers to evaluate the impact of pharmacological therapy in patients with chronic obstructive pulmonary disease. Since then, our scientific understanding of chronic obstructive pulmonary disease has increased considerably; there has been a progressive shift from a one-size-fits-all diagnostic and therapeutic approach to a personalized approach; and many new treatments currently in development will require new endpoints to evaluate their efficacy adequately. Objectives: The emergence of several new relevant outcome measures motivated the authors to review advances in the field and highlight the need to update the content of the original report. Methods: The authors separately created search strategies for the literature, primarily based on their opinions and assessments supported by carefully chosen references. No centralized examination of the literature or uniform criteria for including or excluding evidence were used. Measurements and Main Results: Endpoints, outcomes, and biomarkers have been revisited. The limitations of some of those reported in the American Thoracic Society/European Respiratory Society task force document have been highlighted. In addition, new tools that may be useful, especially in evaluating personalized therapy, have been described. Conclusions: Because the "label-free" treatable traits approach is becoming an important step toward precision medicine, future clinical trials should focus on highly prevalent treatable traits, and this will influence the choice of outcomes and markers to be considered. The use of the new tools, particularly combination endpoints, could help better identify the right patients to be treated with the new drugs.
引用
- Cazzola M, Rogliani P, Barnes PJ, et al. An Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials. Am J Respir Crit Care Med. 2023. PMID: 37236628. doi:10.1164/rccm.202303-0400SO
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。